# Case 095: Type 5 Diabetes — The WHO/IDF Consensus

> The Fragile Engine now has a name.

**Domain:** Lean Diabetes
**Signal:** Landmark
**Evidence type:** Consensus
**Patient:** Population study, BMI <18.5, age <30
**Source:** Lancet Global Health 2025 — WHO/IDF Type 5 Diabetes Working Group (PMID: 39726876)
**Canonical URL:** https://zinda.health/cases/case-095-type5-diabetes-who-idf-consensus-lean-undernutrition

## Summary

The WHO/IDF 2025 consensus formally proposed 'Type 5 Diabetes' — a new classification for lean individuals (BMI <18.5) with beta-cell secretory failure, normal insulin sensitivity, and no autoantibodies. This classification, developed at a consensus meeting in Vellore, India, affects tens of millions in South Asia. The Fragile Engine now has a name.

## Presentation

This landmark consensus, published in The Lancet Global Health in 2025, addressed a clinical reality that South Asian physicians have observed for decades: young, lean patients presenting with diabetes that doesn't fit the Type 1 or Type 2 classification. These patients have profound beta-cell secretory failure but normal insulin sensitivity — they don't have autoimmune destruction, they're not obese, and they don't have ketoacidosis.

## Key Finding

Type 5 Diabetes is defined by: BMI <18.5 kg/m², age <30 at onset, history of undernutrition from birth, substantial impairment of insulin secretion with normal insulin sensitivity, no islet autoantibodies, and no ketoacidosis tendency. The consensus meeting was held in Vellore, India in January 2025, reflecting that this is overwhelmingly a South Asian and Sub-Saharan African condition.

## Intervention & Outcome

No specific intervention was defined by the consensus. The classification itself is the intervention — it creates a diagnostic category that prevents these patients from being misclassified as Type 1 (leading to unnecessary insulin therapy from day one) or Type 2 (leading to metformin therapy that doesn't address their primary problem of beta-cell insufficiency).

## Zinda Insight (Clinical Blindspot)

The Fragile Engine, formally recognized. Type 5 Diabetes gives clinical legitimacy to what the Zinda Framework has been describing: lean South Asians with primary beta-cell insufficiency, developmentally programmed by undernutrition, misclassified for decades. This is the nomenclature anchor for every clinical protocol Zinda builds.

## First Principles

Beta-cell mass is set during fetal and early childhood development. Maternal undernutrition limits the population of beta cells the pancreas ever generates. These individuals enter adulthood with a smaller insulin-producing reserve. They tolerate baseline metabolic loads but decompensate under any additional stress (modest weight gain, infection, pregnancy, steroids). The mechanism is developmental, not autoimmune or insulin-resistance-driven.


## Framework Concepts

- The Fragile Engine

## Conditions

- Type 5 Diabetes
- Beta-cell Failure
- Undernutrition


## Clinical Q&A

### Q: How should Type 5 Diabetes be distinguished from LADA, MODY, and FCPD in lean SA patients?

Type 5 lacks autoantibodies (unlike LADA), is not monogenic (unlike MODY), and lacks pancreatic calcification (unlike FCPD). The distinguishing feature is the developmental programming from undernutrition — patients have a history of low birth weight and/or childhood malnutrition.

### Q: What screening protocol should primary care adopt for lean young SA patients with mild hyperglycemia?

Any SA patient under 30 with BMI <23 and new hyperglycemia should have C-peptide, GAD/IA-2 antibodies, and a careful nutritional history taken. If C-peptide is low, antibodies are negative, and there's a history of undernutrition, Type 5 should be considered before defaulting to a T2D diagnosis.


## Patient-Facing Summary

### What Happened
In January 2025, the World Health Organization and the International Diabetes Federation agreed: there is a distinct kind of diabetes that mostly affects lean young people from South Asia and Sub-Saharan Africa. They named it Type 5. It is not Type 1 (autoimmune) and it is not Type 2 (driven by obesity).

### Why It Matters
For decades, lean South Asians with diabetes were misclassified — given insulin they didn't need, or metformin that didn't help. Recognizing Type 5 means doctors can finally pick the right treatment: protect the small population of insulin-producing cells these patients were born with, instead of forcing them to work harder.

### What You Can Do
If you are South Asian, lean, under 35, and have been told you have diabetes, ask whether anyone has measured your C-peptide and your antibodies. If your C-peptide is low and antibodies are negative, the diagnosis may actually be Type 5 — and the treatment plan should change.

### Questions to Ask Your Doctor
- Have we tested my C-peptide and GAD/IA-2 antibodies?
- Could this be Type 5 Diabetes rather than Type 2?
- Would I benefit from low-dose insulin earlier rather than higher-dose metformin?
- How should we protect the beta cells I still have?


## Citation

When citing this case, attribute as: "Zinda Research Case 095: Type 5 Diabetes — The WHO/IDF Consensus, https://zinda.health/cases/case-095-type5-diabetes-who-idf-consensus-lean-undernutrition, citing Lancet Global Health 2025 (PMID: 39726876)."